Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic ductal adenocarcinoma||not applicable||Cisplatin + Gemcitabine||Phase II||Actionable||In a Phase II trial, patients with pancreatic ductal adenocarcinoma harboring either a germline BRCA1, BRCA2, or PALB2 inactivating mutation demonstrated a response rate of 74.1% (20/27), a median progression-free survival of 10.1 months, a median overall survival of 15.5 months, and a disease control rate of 100% (27/27) when treated with a combination of Gemzar (gemcitabine) and Platinol (cisplatin) (PMID: 31976786).||31976786|